Careload LA (beraprost sodium prolonged release)
/ Toray, Astellas, Kaken Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
May 25, 2019
Effects of sustained-release beraprost in patients with primary glomerular disease or nephrosclerosis: CASSIOPEIR study results.
(PubMed, Ther Apher Dial)
- "HRs (95% CI) in the TRK-100STP 120 and 240 μg vs. placebo were 0.98 (0.78, 1.22) and 0.91 (0.72, 1.14) respectively. The overall incidence of adverse events and adverse drug reactions was comparable between treatment arms."
Clinical • Journal • Chronic Kidney Disease • Nephrology • Renal Disease
1 to 1
Of
1
Go to page
1